This profile is based on publicly available information and may be incomplete or outdated. PE Firm Index is not affiliated with ON24 and does not provide investment advice.

Other portfolio companies of Canaan Partners

6 of 348 shown

Abyrx

Aceiss

Acesion Pharma ApS

Actio Biosciences, Inc.

ACTIVE Network

ActualyzeAI, Inc.

See the full Canaan Partners portfolio.

Other portfolio companies of US Venture Partners

6 of 143 shown

See the full US Venture Partners portfolio.

Is this your company?

Claiming is free and reviewed by hand. Correct facts and add your team.

Claim this profile Suggest a correction

Ownership

Backed by

Canaan Partners

Status: Current

Backed by

US Venture Partners

Status: Exited

For PE-backed companies

DevriX

DevriX runs the websites, integrations and data that bring in revenue, as one accountable engineering and operations team, through acquisitions and exit.

Where DevriX helps

Value creation through the holdRevenue, data, web and AI run as one operating cadence, tied to EBITDA.Add-ons and carve-outsConsolidate or separate platforms and unify reporting after a deal.Exit readinessFind the technology and data issues a buyer's diligence would raise, before it does.

Send DevriX a short brief

A short form on devrix.com. No call to book.

Disclosure: PE Firm Index is maintained by Mario Peshev, who founded and runs DevriX. DevriX listing

Weekly PE M&A and market research, by email

The Growth Shuttle Insider is Mario Peshev's weekly newsletter for PE owners and operators. Each issue carries the week's private equity deals from this index, market data and research, and an essay from Mario.

Free. One email a week. Unsubscribe from any issue. Your address goes to beehiiv, the service that sends the Insider.

Research

The 2027 Digital Value Creation Baseline

1,407 PE-backed companies from 179 sponsors, measured from public sources in October 2026. 15% of service and product companies have the full path from search to CRM.

Read the research

Research by Growth Shuttle and DevriX.